Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 15.5% Potential Upside Indicated by Citigroup

Hikma Pharmaceuticals Plc 15.5% Potential Upside Indicated by Citigroup

Hikma Pharmaceuticals Plc with EPIC/TICKER (LON:HIK) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Citigroup. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Citigroup have set a target price of 1675 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 15.5% from today’s opening price of 1450.5 GBX. Over the last 30 and 90 trading days the company share price has increased 54.5 points and increased 230 points respectively. The 1 year high for the share price is 1536.5 GBX while the 52 week low is 814.2 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,397.13 GBX and a 200 Day Moving Average share price is recorded at 1,153.75. There are currently 78,512,928 shares in issue with the average daily volume traded being 516,132. Market capitalisation for LON:HIK is £3,683,919,369 GBP.